CD274 and non-small cell lung carcinoma: According to National Comprehensive Cancer Network (NCCN) guidelines, pembrolizumab, pembrolizumab with chemotherapy, atezolizumab, and cemiplimab are the first-line immunotherapy regimens for advanced non-squamous NSCLC with PD-L1 expression ≥ 50%.